The antitumor effect induced by an IL-2 ‘no-alpha’ mutein depends on changes in the CD8(+) T lymphocyte/Treg cell balance

High doses of interleukin-2 (IL-2) have been used for the treatment of melanoma and renal cell carcinoma, but this therapy has limited efficacy, with a ~15% response rate. Remarkably, 7%–9% of patients achieve complete or long-lasting responses. Many patients treated with IL-2 experienced an expansi...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmenate, Tania, Montalvo, Galia, Lozada, Sum Lai, Rodriguez, Yaretnis, Ortiz, Yaquelin, Díaz, Claudia, Avellanet, Janet, Kim, Juhee, Surh, Charles D., Graça, Luis, León, Kalet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428827/
https://www.ncbi.nlm.nih.gov/pubmed/36059465
http://dx.doi.org/10.3389/fimmu.2022.974188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428827/
https://www.ncbi.nlm.nih.gov/pubmed/36059465
http://dx.doi.org/10.3389/fimmu.2022.974188

Ejemplares similares